Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Cancer Therapies02:49

Cancer Therapies

10.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.7K
Cancer Therapies02:49

Cancer Therapies

3.0K
3.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Training European Health Care Providers in Adolescent and Young Adult (AYA) Oncology: The Joint Action Networks of Expertise (JANE) on AYA with Cancer Perspective.

Journal of cancer education : the official journal of the American Association for Cancer Education·2026
Same author

Bayesian sequential learning for prognostication in extremity soft tissue sarcoma (BayeSarc): a retrospective, multicentre cohort study.

The Lancet. Oncology·2026
Same author

Training European Health Care Providers in Adolescent and Young Adult (AYA) Oncology: The Joint Action Networks of Expertise (JANE) on AYA with Cancer Perspective.

Journal of cancer education : the official journal of the American Association for Cancer Education·2026
Same author

ASO Visual Abstract: Refining the Contemporary Management of Primary Retroperitoneal Soft Tissue Sarcoma: Outcome Improvement Over Time at a Single Institution.

Annals of surgical oncology·2026
Same author

Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations.

JAMA oncology·2026
Same author

Refining the Contemporary Management of Primary Retroperitoneal Soft Tissue Sarcoma: Outcome Improvement Over Time at a Single Institution.

Annals of surgical oncology·2025

Related Experiment Video

Updated: Apr 12, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.5K

Adjuvant chemotherapy for soft tissue sarcoma.

Paolo G Casali1

  • 1From the Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|May 21, 2015
PubMed
Summary
This summary is machine-generated.

Adjuvant chemotherapy for soft tissue sarcoma (STS) is debated. While not standard, it may benefit high-risk patients, offering a 5-10% survival improvement and potentially better surgical outcomes.

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Related Experiment Videos

Last Updated: Apr 12, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.5K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Area of Science:

  • Oncology
  • Surgical Oncology
  • Medical Oncology

Background:

  • Adjuvant chemotherapy is not a standard treatment for soft tissue sarcoma (STS).
  • Evidence regarding its efficacy is conflicting, despite numerous clinical trials and meta-analyses.
  • High-risk STS patients may consider adjuvant chemotherapy as a shared decision-making option.

Purpose of the Study:

  • To evaluate the role and potential benefits of adjuvant and neoadjuvant chemotherapy in soft tissue sarcoma.
  • To explore personalized treatment approaches based on STS pathology and molecular biology.
  • To inform clinical decision-making in research and practice for STS treatment.

Main Methods:

  • Review of randomized clinical trials and meta-analyses on adjuvant chemotherapy in STS.
  • Analysis of survival rates and distant relapse data.
  • Consideration of neoadjuvant chemotherapy for local advantages and margin quality.

Main Results:

  • Meta-analyses suggest a 5% to 10% benefit in survival and distant relapse rates with adjuvant chemotherapy.
  • Some trials indicate a potential local benefit from preoperative chemotherapy, improving surgical margins.
  • Personalized treatment strategies are being developed based on STS heterogeneity.

Conclusions:

  • Adjuvant chemotherapy for STS remains an option for shared decision-making in high-risk cases due to conflicting evidence.
  • Neoadjuvant chemotherapy may offer local advantages, warranting personalized approaches.
  • Personalization of adjuvant and neoadjuvant treatment decisions requires multidisciplinary expertise and acknowledges evidence limitations.